Estrogen-Progestin Therapy Fails to Slow Atherosclerosis

A recent study found that estrogen-progestin therapy failed to slow the progression of coronary-artery atherosclerosis (plaques in the arteries that feed the heart muscle) in postmenopausal women with the disease.

For their study dubbed the Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trail (WELL-HART), researchers randomly assigned 226 postmenopausal women with known coronary-artery atherosclerosis to one of three groups: a control group that received “usual care,” an estrogen group that received 17β-estradiol therapy, or an estrogen-progestin group that received the 17β-estradiol plus medroxyprogesterone.*

The study found no significant difference between the three groups in the progression of atherosclerosis as seen on the cardiac angiograms.

The researchers noted, however, that these results are “strikingly different” from those of the Estrogen in the Prevention of Atherosclerosis Trial (EPAT) study, in which oral 17β-estradiol alone slowed thickening of the carotid artery wall. The time from menopause was 5-10 years less in the EPAT study than in the WELL-HART study, however, which suggests that hormone replacement therapy may play a role in preventing coronary artery disease early after menopause, but may become detrimental after a certain number of years.

Reference
Copyright of Life Extension is the property of Life Extension Foundation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder’s express written permission. However, users may print, download, or email articles for individual use.